Download Image
    
Share
  
Post
Apilimod for COVID-19
1 study with 141 patients
Hospital Icon Control
Hospital Icon Apilimod Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Apilimod studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -199% Mortality -199% RCTs -199% Early -199% Favorsapilimod Favorscontrol
Apilimod is an oral, small molecule drug that inhibits the human PIKfyve kinase.
Apr 19
2021
 Young et al., NCT04446377 A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19
199% higher mortality (p=1), 100% higher combined mortality/hospitalization (p=1), and 109% worse recovery (p=0.43). RCT 142 COVID-19 patients showing no significant differences with apilimod treatment.